The National Institutes of Health is undertaking an extended study of the health effects that East Palestine, Ohio, residents ...

Israelis lack sleep and experience high anxiety amid the wars with Hamas and Iran as the two Middle East nations exchange ...

Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.

Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Eli Lilly just dropped $1 billion—plus a $300 million bonus if trials go well—on gene therapy firm Verve, aiming to spice up ...

Nucor shares are rising Wednesday after the steelmaker outlined better second-quarter profit projections than analysts had ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.

Asian shares are mixed and oil prices have advanced after the escalation of conflict in the Middle East hit Wall Street.

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...